EQS-News: Newron Pharmaceuticals S.p.A. / Key word: Study results
Data from Newron’s study 014/015 and an evenamide clinical development outlook presented at the 2024 Annual.
Newron Pharmaceuticals S p A : Newron Reports Exceptional One-year Results of Study 014/15 With Evenamide in Treatment-resistant Schizophrenia (TRS) finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
EQS-News: Newron reports exceptional one-year results of study 014/15 with evenamide in treatment-resistant schizophrenia (TRS) finanzen.at - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanzen.at Daily Mail and Mail on Sunday newspapers.
EQS-News: Newron Pharmaceuticals S.p.A. / Key word: Study results
Newron reports exceptional one-year results of study 014/15 with evenamide in treatment-resistant schizophrenia.